Endocrinology, Vol 130, 2597-2601, Copyright © 1992 by Endocrine Society

ARTICLES

Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8)

Y Liel, S Kraus, J Levy and S Shany
Department of Medicine, Soroka University Hospital, Beer-Sheva, Israel.

A detailed understanding of the mechanism of action of estrogen on bones is still lacking. The present study was designed to examine possible modulation by 17 beta-estradiol (E2) on the effects of 1,25- dihydroxyvitamin D3 [1,25-(OH)2D3] and on vitamin D receptors (VDR) in the ROS 17/2.8 osteoblast-like cell line. Cells were grown in phenol- red free medium supplemented with charcoal-stripped fetal calf serum (FCS). Total cellular VDR were measured in cell homogenates after extraction with a KCl hypertonic buffer. VDR-binding capacity doubled in the presence of 10 nM E2 (16.2 +/- 2.3 vs. 7.0 +/- 1.3 fmol/mg protein, respectively; P less than 0.01), while the Kd for 1,25-(OH)2D3 did not change (approximately 0.1 nM). Tamoxifen alone had no effect on VDR, while it completely abolished the E2-induced increase in VDR, indicating that the effect was specific for E2 and estrogen receptor mediated. 1,25-(OH)2D3 inhibited cell proliferation, determined by [3H] thymidine incorporation to DNA, in a dose-dependent fashion between 0.01-100 nM. The inhibitory effect of 1,25-(OH)2D3 on cell proliferation was significantly augmented in the presence of E2 (10 nM). 1,25-(OH)2D3 increased osteocalcin secretion to the medium by the cells in a dose-dependent fashion between 0.01-100 nM. In the presence of E2 (10 nM), maximal osteocalcin secretion in response to 1,25- (OH)2D3 was 3.5-fold higher than that in response to 1,25-(OH)2D3 alone. These results indicate that E2 modulates 1,25-(OH)2D3 activity in osteoblast-like cells, and that this effect can be attributed to an increase in VDR.

This article has been cited by other articles:

				S. Abbas, J. Linseisen, T. Slanger, S. Kropp, E. J. Mutschelknauss, D. Flesch-Janys, and J. Chang-Claude Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study Carcinogenesis, January 1, 2008; 29(1): 93 - 99. [Abstract] [Full Text] [PDF]

				L. A. Gilad and B. Schwartz Association of estrogen receptor {beta} with plasma-membrane caveola components: implication in control of vitamin D receptor J. Mol. Endocrinol., June 1, 2007; 38(6): 603 - 618. [Abstract] [Full Text] [PDF]

				L. A. Gilad, O. Tirosh, and B. Schwartz Phytoestrogens regulate transcription and translation of vitamin D receptor in colon cancer cells. J. Endocrinol., November 1, 2006; 191(2): 387 - 398. [Abstract] [Full Text] [PDF]

				L. A. Gilad, T. Bresler, J. Gnainsky, P. Smirnoff, and B. Schwartz Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells J. Endocrinol., June 1, 2005; 185(3): 577 - 592. [Abstract] [Full Text] [PDF]

				J. A. Huhtakangas, C. J. Olivera, J. E. Bishop, L. P. Zanello, and A. W. Norman The Vitamin D Receptor Is Present in Caveolae-Enriched Plasma Membranes and Binds 1{alpha},25(OH)2-Vitamin D3 in Vivo and in Vitro Mol. Endocrinol., November 1, 2004; 18(11): 2660 - 2671. [Abstract] [Full Text] [PDF]

				S. Palomba, F. G. Numis, G. Mossetti, D. Rendina, P. Vuotto, T. Russo, F. Zullo, C. Nappi, and V. Nunziata Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes Hum. Reprod., January 1, 2003; 18(1): 192 - 198. [Abstract] [Full Text] [PDF]

				Y. Liel, S. Shany, P. Smirnoff, and B. Schwartz Estrogen Increases 1,25-Dihydroxyvitamin D Receptors Expression and Bioresponse in the Rat Duodenal Mucosa Endocrinology, January 1, 1999; 140(1): 280 - 285. [Abstract] [Full Text]